Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1960 1
1961 2
1963 3
1964 2
1965 1
1966 4
1967 4
1968 2
1969 2
1970 2
1971 1
1972 1
1973 2
1974 3
1975 5
1976 7
1977 4
1978 4
1979 8
1980 17
1981 2
1982 10
1983 15
1984 10
1985 5
1986 8
1987 8
1988 19
1989 13
1990 9
1991 6
1992 11
1993 19
1994 21
1995 33
1996 32
1997 28
1998 21
1999 36
2000 28
2001 24
2002 23
2003 30
2004 25
2005 39
2006 29
2007 41
2008 33
2009 45
2010 38
2011 59
2012 68
2013 44
2014 42
2015 50
2016 55
2017 36
2018 44
2019 59
2020 55
2021 52
2022 45
2023 22
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

1,273 results

Results by year

Filters applied: . Clear all
Page 1
Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria.
Thompson AJ, Banwell BL, Barkhof F, Carroll WM, Coetzee T, Comi G, Correale J, Fazekas F, Filippi M, Freedman MS, Fujihara K, Galetta SL, Hartung HP, Kappos L, Lublin FD, Marrie RA, Miller AE, Miller DH, Montalban X, Mowry EM, Sorensen PS, Tintoré M, Traboulsee AL, Trojano M, Uitdehaag BMJ, Vukusic S, Waubant E, Weinshenker BG, Reingold SC, Cohen JA. Thompson AJ, et al. Among authors: hartung hp. Lancet Neurol. 2018 Feb;17(2):162-173. doi: 10.1016/S1474-4422(17)30470-2. Epub 2017 Dec 21. Lancet Neurol. 2018. PMID: 29275977 Review.
Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis.
Hauser SL, Bar-Or A, Comi G, Giovannoni G, Hartung HP, Hemmer B, Lublin F, Montalban X, Rammohan KW, Selmaj K, Traboulsee A, Wolinsky JS, Arnold DL, Klingelschmitt G, Masterman D, Fontoura P, Belachew S, Chin P, Mairon N, Garren H, Kappos L; OPERA I and OPERA II Clinical Investigators. Hauser SL, et al. Among authors: hartung hp. N Engl J Med. 2017 Jan 19;376(3):221-234. doi: 10.1056/NEJMoa1601277. Epub 2016 Dec 21. N Engl J Med. 2017. PMID: 28002679 Free article. Clinical Trial.
Guillain-Barré syndrome.
Yuki N, Hartung HP. Yuki N, et al. Among authors: hartung hp. N Engl J Med. 2012 Jun 14;366(24):2294-304. doi: 10.1056/NEJMra1114525. N Engl J Med. 2012. PMID: 22694000 Review. No abstract available.
Acquired aplastic anemia in children.
Hartung HD, Olson TS, Bessler M. Hartung HD, et al. Pediatr Clin North Am. 2013 Dec;60(6):1311-36. doi: 10.1016/j.pcl.2013.08.011. Epub 2013 Oct 16. Pediatr Clin North Am. 2013. PMID: 24237973 Free PMC article. Review.
Ublituximab versus Teriflunomide in Relapsing Multiple Sclerosis.
Steinman L, Fox E, Hartung HP, Alvarez E, Qian P, Wray S, Robertson D, Huang D, Selmaj K, Wynn D, Cutter G, Mok K, Hsu Y, Xu Y, Weiss MS, Bosco JA, Power SA, Lee L, Miskin HP, Cree BAC; ULTIMATE I and ULTIMATE II Investigators. Steinman L, et al. Among authors: hartung hp. N Engl J Med. 2022 Aug 25;387(8):704-714. doi: 10.1056/NEJMoa2201904. N Engl J Med. 2022. PMID: 36001711 Clinical Trial.
New drugs for multiple sclerosis: new treatment algorithms.
Cree BAC, Hartung HP, Barnett M. Cree BAC, et al. Among authors: hartung hp. Curr Opin Neurol. 2022 Jun 1;35(3):262-270. doi: 10.1097/WCO.0000000000001063. Curr Opin Neurol. 2022. PMID: 35674067 Review.
Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis.
Montalban X, Hauser SL, Kappos L, Arnold DL, Bar-Or A, Comi G, de Seze J, Giovannoni G, Hartung HP, Hemmer B, Lublin F, Rammohan KW, Selmaj K, Traboulsee A, Sauter A, Masterman D, Fontoura P, Belachew S, Garren H, Mairon N, Chin P, Wolinsky JS; ORATORIO Clinical Investigators. Montalban X, et al. Among authors: hartung hp. N Engl J Med. 2017 Jan 19;376(3):209-220. doi: 10.1056/NEJMoa1606468. Epub 2016 Dec 21. N Engl J Med. 2017. PMID: 28002688 Free article. Clinical Trial.
Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial.
Cree BAC, Bennett JL, Kim HJ, Weinshenker BG, Pittock SJ, Wingerchuk DM, Fujihara K, Paul F, Cutter GR, Marignier R, Green AJ, Aktas O, Hartung HP, Lublin FD, Drappa J, Barron G, Madani S, Ratchford JN, She D, Cimbora D, Katz E; N-MOmentum study investigators. Cree BAC, et al. Among authors: hartung hp. Lancet. 2019 Oct 12;394(10206):1352-1363. doi: 10.1016/S0140-6736(19)31817-3. Epub 2019 Sep 5. Lancet. 2019. PMID: 31495497 Clinical Trial.
Epstein-Barr Virus in Multiple Sclerosis: Theory and Emerging Immunotherapies.
Bar-Or A, Pender MP, Khanna R, Steinman L, Hartung HP, Maniar T, Croze E, Aftab BT, Giovannoni G, Joshi MA. Bar-Or A, et al. Among authors: hartung hp. Trends Mol Med. 2020 Mar;26(3):296-310. doi: 10.1016/j.molmed.2019.11.003. Epub 2019 Dec 17. Trends Mol Med. 2020. PMID: 31862243 Free PMC article. Review.
Eculizumab versus rituximab in generalised myasthenia gravis.
Nelke C, Schroeter CB, Stascheit F, Pawlitzki M, Regner-Nelke L, Huntemann N, Arat E, Öztürk M, Melzer N, Mergenthaler P, Gassa A, Stetefeld H, Schroeter M, Berger B, Totzeck A, Hagenacker T, Schreiber S, Vielhaber S, Hartung HP, Meisel A, Wiendl H, Meuth SG, Ruck T. Nelke C, et al. Among authors: hartung hp. J Neurol Neurosurg Psychiatry. 2022 May;93(5):548-554. doi: 10.1136/jnnp-2021-328665. Epub 2022 Mar 4. J Neurol Neurosurg Psychiatry. 2022. PMID: 35246490 Free PMC article.
1,273 results